胰岛素样生长因子1受体及其通路在原发性肝癌中的机制及进展

赵曌; 亓文骞; 赵平

doi:10.3969/j.issn.1001-5256.2017.04.038

胰岛素样生长因子1受体及其通路在原发性肝癌中的机制及进展

DOI: 10.3969/j.issn.1001-5256.2017.04.038

吉林大学第三医院消化内科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 288
- HTML全文浏览量: 33
- PDF下载量: 147
- 被引次数: 0
出版历程
- 收稿日期: 2017-01-13
- 出版日期: 2017-04-20

Research advances in insulin-like growth factor 1 receptor and its pathway in diagnosis and treatment of primary liver cancer

Department of Gastroenterology, The Third Hospital of Jilin University

摘要

摘要: 胰岛素样生长因子1受体（IGF-1R）的生物学功能主要表现为形成并维持细胞的转化表型,参与细胞增殖、分化,抑制细胞的凋亡。除此之外,IGF-1R对细胞周期具有调节作用,与表皮生长因子、血小板衍生生长因子共同作用,介导细胞周期从G1期进入S期。过度表达的IGF-1R己经成为原发性肝癌影像诊断及定位治疗的热点靶蛋白之一。抑制IGF-1R的表达或功能可有效控制肿瘤细胞生长和转移,并增强其对化疗、放疗的敏感性。综述了IGF-1R及其通路在原发性肝癌诊断及治疗中的作用及意义。
- 肝肿瘤 /
- 受体,IGF1型 /
- 诊断 /
- 治疗 /
- 综述
Abstract: The main biological functions of insulin-like growth factor 1 receptor ( IGF-1R) include formation and maintenance of transformed cell phenotype, involvement in cell proliferation and differentiation, and inhibition of cell apoptosis. In addition, IGF-1R regulates cell cycle and works with epidermal growth factor and platelet-derived growth factor to mediate cells to enter S phase from G1 phase. Overexpressed IGF-1R has become one of the target proteins for diagnostic imaging and localization therapy for primary liver cancer. Inhibition of the expression or function of IGF-1R can effectively control the growth and metastasis of tumor cells and enhance their sensitivity to chemotherapy and radiotherapy. This article reviews the role and significance of IGF-1R and its pathway in the diagnosis and treatment of primary liver cancer.
- liver neoplasms /
- receptor, IGF type 1 /
- diagnosis /
- therapy /
- review

HTML全文

参考文献(43)

[1]FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al.Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012[J].Int J Cancer, 2015, 136 (5) :e359-e386.

[2] JEMAL A, BRAY F, CENTER MM, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61 (2) :69-90.

[2]ABBAS A, MEDVEDEV S, SHORES N, et al.Epidemiology of metastatic hepatocellular carcinoma, a nationwide perspective[J].Dig Dis Sci, 2014, 59 (11) :2813-2820.

[4]CHEN JG, ZHANG SW.Liver cancer epidemic in China:past, present and future[C]//Seminars in cancer biology.Academic Press, 2011, 21 (1) :59-69.

[5]SECCARECCIA E, BRODT P.The role of the insulin-like growth factor-I receptor in malignancy:an update[J].Growth Horm IGF Res, 2012, 22 (6) :193-199.

[6]GIRNITA L, WORRALL C, TAKAHASHI SI, et al.Something old, something new and something borrowed:emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation[J].Cell Mol Life Sci, 2014, 71 (13) :2403-2427.

[7]BRAHMKHATRI VP, PRASANNA C, ATREYA HS.Insulinlike growth factor system in cancer:novel targeted therapies[J].Biomed Res Int, 2015, 2015:538019.

[8]VALENCIANO A, HENRQUEZ-HERNNDEZ LA, MORENO M, et al.Role of IGF-1 receptor in radiation response[J].Transl Oncol, 2012, 5 (1) :1-9.

[9]HAISA M.The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer[J].J Int Med Res, 2013, 41 (2) :253-264.

[10]TAMIMI RM, COLDITZ GA, WANG Y, et al.Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer[J].Breast Cancer Res Treat, 2011, 128 (1) :243-250.

[11]WU J, ZHU AX.Targeting insulin-like growth factor axis in hepatocellular carcinoma[J].J Hematol Oncol, 2011, 4 (1) :30.

[12]KESSENBROCK K, PLAKS V, WERB Z.Matrix metalloproteinases:regulators of the tumor microenvironment[J].Cell, 2010, 141 (1) :52-67.

[13]UNGEWITTER E, SCRABLE H.Delta40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs[J].Genes Dev, 2010, 24 (21) :2408-2419.

[14]DURFORT T, TKACH M, MESCHANINOVA MI, et al.Small interfering RNA targeted to IGF-1R delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model[J].PLo S One, 2012, 7 (1) :e29213.

[15]di COSTANZO GG, de STEFANO G, TORTORA R, et al.Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma[J].Future Oncology, 2015, 11 (6) :943-951.

[16]ARNALDEZ FI, HELMAN LJ.Targeting the insulin growth factor receptor 1[J].Hematol Oncol Clin North Am, 2012, 26 (3) :527-542.

[17]KASEB AO, MORRIS JS, HASSAN MM, et al.Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma[J].J Clin Oncol, 2011, 29 (29) :3892-3899.

[18]DENG GL, ZENG S, SHEN H.Chemotherapy and target therapy for hepatocellular carcinoma:new advances and challenges[J].World J Hepatol, 2015, 7 (5) :787-798.

[19]TOVAR V, ALSINET C, VILLANUEVA A, et al.IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage[J].J Hepatol, 2010, 52 (4) :550-559.

[20]NAULT JC.Reports from the International Liver Cancer Association (ILCA) congress 2014[J].J Hepatol, 2015, 62 (2) :477-482.

[21]ARCARO A.Targeting the insulin-like growth factor-1 receptor in human cancer[J].Front Pharmacol, 2013, 4:30.

[22]CHEN HX, SHARON E.IGF-1R as an anti-cancer target-trials and tribulations[J].Chin J Cancer, 2013, 32 (5) :242-252.

[23]CAMIRAND A, ZAKIKHANI M, YOUNG F, et al.Inhibition of insulin-like growth factor-1 receptor signaling enhances growthinhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells[J].Breast Cancer Res, 2005, 7 (4) :r570-r579.

[24]DEUTSCH E, MAGGIORELLA L, WEN B, et al.Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation[J].Br J Cancer, 2004, 91 (9) :1735-1741.

[25]SHEN Z.Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line[J].Exp Ther Med, 2011, 2 (6) :1091-1095.

[26]YAO WF, LIU JW, SHENG GL, et al.Blockade of IGF-IR exerts anticancer effects in hepatocellular carcinoma[J].Mol Med Rep, 2011, 4 (4) :719-722.

[27]GARCA-ECHEVERRA C, PEARSON MA, MARTI A, et al.In vivo antitumor activity of NVP-AEW541——a novel, potent, and selective inhibitor of the IGF-IR kinase[J].Cancer Cell, 2004, 5 (3) :231-239.

[28]HPFNER M, HUETHER A, SUTTER AP, et al.Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells[J].Biochem Pharmacol, 2006, 71 (10) :1435-1448.

[29]CHANG AY, WANG M.In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma[J].Anticancer Drugs, 2013, 24 (3) :251-259.

[30]WANG N, LU Y, PINARD M, et al.Sustained production of a soluble IGF-I receptor by gutless adenovirus-transduced host cells protects from tumor growth in the liver[J].Cancer Gene Ther, 2013, 20 (4) :229-236.

[31]YANG N, EKANEM NR, SAKYI CA, et al.Hepatocellular carcinoma and miRNAs:New perspectives on therapeutics and diagnostics[J].Adv Drug Deliv Rev, 2015, 81:62-74.

[32]KENYON CJ.The genetics of ageing[J].Nature, 2010, 464 (7288) :504-512.

[33]BAI S, NASSER MW, WANG B, et al.MiRNAs-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib[J].J Biol Chem, 2009, 284 (46) :32015-32027.

[34]WANG B, WANG H, YANG Z.MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R[J].PLo S One, 2012, 7 (10) :e47053.

[35]ARAVALLI RN.Development of miRNAs therapeutics for hepatocellular carcinoma[J].Diagnostics, 2013, 3 (1) :170-191.

[36]JUNG HJ, SUH Y.Regulation of IGF-1 signaling by microRNAs[J].Front Genet, 2015, 5:472.

[37]CHEN WJ, YANG X, YE ZH, et al.Appraising microRNA-99a as a novel prognostic biomarker across 21 human cancer types based on data from the cancer genome atlas[J].Int J Clin Exp Med, 2017, 10 (1) :563-574.

[38]LAW PT, CHING AK, CHAN AW, et al.MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma[J].Carcinogenesis, 2012, 33 (6) :1134-1141.

[39]SU H, YANG JR, XU T, et al.MiRNAs-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity[J].Cancer Res, 2009, 69 (3) :1135-1142.

[40]ZHANG W, LIU K, LIU S, et al.MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma[J].Tumor Biol, 2015, 36 (12) :9779-9788.

[41]YANG X, ZANG J, PAN X, et al.miR-503 inhibits proliferation making human hepatocellular carcinoma cells susceptible to 5 fluorouracil by targeting EIF4E[J].Oncol Rep, 2017, 37 (1) :563-570.

[42]ZHOU B, MA R, SI W, et al.MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth[J].Cancer Lett, 2013, 333 (2) :159-169.

[43]SU X, CHENG K, LIU Y, et al.PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule[J].Amino Acids, 2015, 47 (7) :1409-1419.

施引文献

资源附件(0)

访问统计